Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Glazer

Procedural Dermatology Buffalo Grove, IL Medical Doctor

NPI 1770587206 CMS profile 34750

600 W Lake Cook Rd, Ste 110, Buffalo Grove, IL 60089

Open in the dashboard

General payments

$37,737

540 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,700 paid to institutions, not to them · program year 2021

Through program year 2025, Scott Glazer of Buffalo Grove, IL is reported in the CMS Open Payments database as having received $37,737 across 540 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,700 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,787 88
2024 General $4,473 73
2023 General $4,484 75
2022 General $16,998 82
2021 General $5,135 69
2020 General $682 46
2019 General $1,179 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Glazer
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Scott Glazer were reported at $4,787. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Scott Glazer Procedural Dermatology median Middle half National median
2019 $1,179 $454 $152–$1,260 $163
2020 $682 $243 $90–$835 $114
2021 $5,135 $337 $102–$1,128 $132
2022 $16,998 $443 $119–$1,654 $149
2023 $4,484 $583 $137–$1,838 $160
2024 $4,473 $611 $132–$1,835 $164
2025 $4,787 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $19,423 157 payments
  2. AbbVie, Inc. $10,861 97 payments
  3. EPI Health, LLC $1,534 2 payments
  4. Janssen Biotech, Inc. $897 66 payments
  5. Genzyme Corporation $718 31 payments
  6. Revance Therapeutics, Inc. $545 9 payments
  7. Sun Pharmaceutical Industries Inc. $437 23 payments
  8. Lilly USA, LLC $395 17 payments
  9. UCB, Inc. $334 11 payments
  10. Galderma Laboratories, L.P. $318 15 payments
  11. Other $2,274 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,286 58 payments
  2. Food and Beverage $8,233 462 payments
  3. Consulting Fee $2,900 2 payments
  4. Education $318 18 payments
Products named General payments · program years 2019–2025
  1. WYNZORA $1,534 2 payments
  2. DUPIXENT $943 38 payments
  3. BOTOX $865 60 payments
  4. TREMFYA $730 59 payments
  5. BOTOX COSMETIC $611 70 payments
  6. DAXXIFY $545 9 payments
  7. STELARA $461 36 payments
  8. SIMPONI ARIA $406 22 payments
  9. SIMPONI $406 22 payments
  10. SKYRIZI $397 19 payments
  11. Other $4,350 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,526

Median for Dermatology: 534

Drug cost

$202,856

Median for Dermatology: $67,151

Branded share of claims

5.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 19 $128,629
Dupixent Pen Dupilumab Brand 13 $48,389
Betamethasone Dipropionate Generic 144 $5,007
Clobetasol Propionate Generic 88 $3,201
Minoxidil Generic 241 $3,019
Doxycycline Hyclate Generic 101 $2,552
Ketoconazole Generic 128 $2,290
Triamcinolone Acetonide Generic 229 $2,064
Mometasone Furoate Generic 104 $1,441
Metronidazole Generic 14 $1,303

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$1,122,610

Of which drugs: $307,615

Medicare patients

3,527

Average age 77

Services billed

19,423

1,813 women, 1,714 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 48%
Ischemic heart disease 25%
Diabetes 18%
Cancer 18%
Osteoporosis 17%
Atrial fibrillation 16%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 164 528 $369

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $323
  • Regeneron Healthcare Solutions, Inc. $35
$358 13 —
TALTZ
  • Lilly USA, LLC $137
$137 19 —
RINVOQ
  • AbbVie, Inc. $92
$92 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $79
$79 — —
ADBRY
  • LEO Pharma Inc. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

540 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record